Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment

Annals of Oncology

Volumn 17, Issue 11, 2006, Pages 1677-1686

  Maluf, F C ^a,b   Cordon Cardo, C ^a   Verbel, D A ^a   Satagopan, J M ^a   Boyle, M G ^a   Herr, H ^a   Bajorin, D F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bcl 2; Mdm 2; P53; Prognosis; Transitional cell carcinoma; Urothelial tract cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MUSCLE METASTASIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

EID: 33750591009     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl289     Document Type: Article

References (66)

1. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866.
2. Leibovitch I, Ben-Chaim J, Ramon J et al. The significance of ureteral obstruction in invasive transitional cell carcinoma of the urinary bladder. J Surg Oncol 1993; 52: 31-35.
3. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: A review. Eur Urol 2003; 44: 672-681.
4. Cheng L, Pan CX, Yang XJ et al. Small cell carcinoma of the urinary bladder: A clinicopathologic analysis of 64 patients. Cancer 2004; 101: 957-962.
5. Kaelin WG Jr. The emerging p53 gene family. J Natl Cancer Inst 1999; 91: 594-598.
6. Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol 1999; 10: 1011-1021.
7. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998; 16: 311-320.
8. Sarkis A, Bajorin D, Reuter V et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384-1390.
9. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993; 85: 53-59.
10. Stein JP, Ginsberg DA, Grossfeld GD et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072-1079.
11. Logothetis CJ, Xu H, Ro JY et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992; 84: 1256-1261.
12. Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251-1256.
13. Cordon-Cardo C, Zhang Z-F, Dalbagni G et al. Cooperative effects of 53 and pRb alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-1221.
14. Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007-1013.
15. Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 2005; 6: 678-686.
16. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
17. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
18. Pfister C, Moore L, Allard P et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999; 5: 4079-4084.
19. Lianes P, Orlow I, Zhang ZF et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86: 1325-1330.
20. Barbareschi M, Girlando S, Fellin G et al. Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol Res 1995; 22: 349-352.
21. Shiina H, Igawa M, Shigeno K et al. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 1999; 56: 239-247.
22. Jahnson S, Karlsson MG. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 2000; 89: 619-629.
23. Schmitz-Drager BJ, Kushima M, Goebell P et al. p53 and MDM2 in the development and progression of bladder cancer. Eur Urol 1997; 32: 487-493.
24. Jiang M, Shao ZM, Wu J et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997; 74: 529-534.
25. Tanner B, Hengstler JG, Laubscher S et al. mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997; 74: 438-442.
26. Osman I, Sherman E, Singh B et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: Impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002; 20: 2980-2987.
27. Dellas A, Schultheiss E, Almendral AC et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer 1997; 74: 421-425.
28. Moch H, Sauter G, Gasser TC et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 1997; 25 (Suppl 1): S25-S30.
29. Hockenbery D, Nunez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
30. Nowell PC, Croce CM. Philip Levine award lecture. Chromosome translocations and oncogenes in human lymphoid tumors. Am J Clin Pathol 1990; 94: 229-237.
31. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res 1992; 52: 6940-6944.
32. Pezzella F, Turley H, Kuzu I et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
33. Neri A, Marrelli D, Roviello F et al. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat 2006; In press.
34. Hussain SA, Ganesan R, Hiller L et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 2003; 10: 571-576.
35. Uchida T, Minei S, Gao JP et al. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol Rep 2002; 9: 253-259.
36. Schultz P, Herr HW, Zhang ZF et al. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994; 12: 1394-1401.
37. TNM classification of malignant tumors. In Hermanek P, Sobin LH (eds): International Union Against Cancer, 4th edition. New York: Springer 1987; 143.
38. Cordon-Cardo C, Dalbagni G, Saez GT et al. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347-353.
39. Ow K, Delprado W, Fisher R et al. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. J Pathol 2000; 191: 39-47.
40. Ye D, Li H, Qian S et al. bcl-2/bax expression and p53 gene status in human bladder cancer: Relationship to early recurrence with intravesical chemotherapy after resection. J Urol 1998; 160: 2025-2029.
41. Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumors. Histopathology 1996; 28: 135-140.
42. Bilim V, Tomita Y, Kawasaki T et al. Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst 1996; 88: 686-688.
43. Pollack A, Wu C, Czerniak B et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997; 3: 1823-1829.
44. Pfister C, Larue H, Moore L et al. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. Int J Cancer 2000; 89: 100-104.
45. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
46. Wang Y, Szekely L, Okan I et al. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma cell line. Oncogene 1993; 8: 3427-3431.
47. Esrig D, Spruck CH III, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-1397.
48. Moch H, Sauter G, Moore D et al. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch 1993; 423: 329-334.
49. Lacombe L, Dalbagni G, Zhang ZF et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome. J Clin Oncol 1996; 14: 2646-2652.
50. Caliskan M, Turkeri LN, Mansuroglu B et al. Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 1997; 79: 373-377.
51. Pfister C, Flaman JM, Dunet F et al. P53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol 1999; 162: 69-73.
52. Garcia del Muro X, Condom E, Vigues F et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004; 100: 1859-1867.
53. Cote RJ, Esrig D, Groshen S et al. p53 and treatment of bladder cancer. Nature 1997; 385: 123-125.
54. Kakehi Y, Ozdemir E, Habuchi T et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 1998; 89: 214-220.
55. Sjostrom J, Blomqvist C, Heikkila P et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000; 6: 3103-3110.
56. Miyake H, Hara I, Yamanaka K et al. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. J Urol 1999; 162: 2176-2181.
57. Rodel C, Grabenbauer GG, Rodel F et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000; 46: 1213-1221.
58. Matsumoto H, Wada T, Fukunaga K et al. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 2004; 34: 124-130.
59. Weiss C, Rodel F, Wolf I et al. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome? Strahlenther Onkol 2005; 181: 213-222.
60. Sanchez-Carbayo M, Socci ND, Lozano J et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778-789.
61. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: Ten-year outcome. J Clin Oncol 1998; 16: 1298-1301.
62. Wang H, Zeng X, Oliver P et al. MDM2 oncogene as a target for cancer therapy: An antisense approach. Int J Oncol 1999; 15: 653-660.
63. Sato N, Mizumoto K, Maehara N et al. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1. Anticancer Res 2000; 20: 837-842.
64. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000; 86: 855-862.
65. Gleave M, Tolcher A, Miyake H et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999; 5: 2891-2898.
66. Schaaf A, Sagi S, Langbein S et al. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 2004; 22: 188-192.